Dicot reports good results from preclinical toxicology studies

Uppsala, October 11, 2022. Dicot reports that the preclinical toxicology studies that are now being conducted, so far show that the drug candidate LIB-01 has a good safety profile.

Dicot is now conducting several toxicology studies within the framework of the preclinical program with the drug candidate LIB-01. Studies of the toxicity of a drug candidate are a necessary and important part of the authorities' approval process for start of clinical studies in humans.

Dicot has performed studies with a subcutaneous formulation and now the first toxicology study with an oral formulation has been conducted. LIB-01 has so far shown to be well tolerated with a good safety profile and no signs of adverse effects have been seen in the animal studies.

A number of studies remain to be conducted before the company's toxicology program is complete.

"These results are very promising and are consistent with our expectation that LIB-01 has a good safety profile. We are now working further with great confidence," comments Elin Trampe, CEO of Dicot.

This disclosure contains information that Dicot AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 11-10-2022 15:00 CET.

Elin Trampe, CEO
Tel: +46 739 80 14 08
elin.trampe@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.